Swiss contract manufacturer (CDMO) producing active pharmaceutical ingredients and finished drug products for pharma clients.
Swiss contract manufacturer (CDMO) producing active pharmaceutical ingredients and finished drug products for pharma clients.
Makes active ingredients and finished tablets or capsules to the customer's specification under supply agreements, so it sells manufacturing capacity and know-how, not drugs under its own name. Once a product is transferred, orders tend to continue for as long as the drug sells. Sites span Europe, the US and China.
In one line: A Swiss Lonza / Catalent.
Moat: narrow (regulatory licence, customer qualification, scale). FDA/EMA-approved manufacturing sites are costly and slow to requalify or replace.
Headquarters: Zofingen, Switzerland · Founded: 1873 · Employees: 3,891
Size Siegfried (SFZN.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $3.51B, the 71st largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 67.75 on 18 Nov 2026.
Performance Over six months the shares fell 17.4%, against +12.3% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 3.6% over the last twelve months (peer median +10.3%); the operating margin is 15.7% (peer median 12.2%).
Valuation It trades at 16.8× forward earnings against a peer median of 20.1× (5th cheapest of 12).
Capital Return on invested capital runs 4.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 19 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 1.34B | CHF 1.33B | CHF 1.29B | CHF 1.27B | CHF 1.23B |
| Revenue growth | — | +3% | +2% | +3% | — |
| Gross profit | CHF 362M | CHF 352M | CHF 329M | CHF 320M | CHF 319M |
| EBITDA | CHF 313M | CHF 307M | CHF 277M | CHF 249M | CHF 310M |
| Net income | CHF 171M | CHF 169M | CHF 160M | CHF 113M | CHF 156M |
| Free cash flow | -CHF 18.2M | CHF 9.97M | -CHF 5.24M | CHF 72.2M | CHF 30.9M |
| Capital expenditure | CHF 201M | CHF 231M | CHF 181M | CHF 137M | CHF 115M |
| Total debt | n/a | CHF 575M | CHF 490M | CHF 525M | CHF 590M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Siegfried SFZN.SW | $3.51B | -17% | +4% | 16% | 16.8× | n/a |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| WuXi AppTec 603259.SS | $64.2B | +40% | +32% | 43% | 17.0× | 7.2% |
| Asymchem Laboratories (Tianjin) 002821.SZ | $7.27B | +20% | +18% | 17% | 37.4× | n/a |
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SFZN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | +4.5% | 5th lowest of 21 |
| 6-month return | -17.4% | +12.3% | 3rd lowest of 20 |
| Distance from 52-week high | -33.3% | -21.3% | 4th lowest of 21 |
| Revenue growth (TTM) | +3.6% | +10.3% | 7th lowest of 18 |
| Operating margin | 15.7% | 12.2% | 7th highest of 16 |
| Forward P/E | 16.8× | 20.1× | 5th cheapest of 12 |
| ROIC minus cost of capital | +4.3 pp | +3.7 pp | 8th highest of 16 |
| EV / EBITDA | 12.1× | 23.9× | 4th cheapest of 9 |
| Net debt / EBITDA | 2.6× | 1.2× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |